Celgene's Vidaza to Retain Proprietary Clinical Gold Standard Status for the Treatment of Myelodysplastic Syndromes
TradingMarkets.com
Posted on: Wed, 28 Apr 2010 00:59:22 EDT
Apr 28, 2010 (Close-Up Media via COMTEX)
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013...
WASHINGTON, DC -- April 5, 2010 -- A genetic treatment for leukaemia may improve remission and survival outcomes in elderly patients compared to existing remedies such as intensive chemotherapy, according to a report published in the latest issue of Proceedings of the National Academy of Sciences (PNAS).
Carlo Croce, MD, Department of Immunology and Medical Genetics, Ohio State University, Columbus, Ohio, and colleagues administered decitabine,...
Updated NCCN Guidelines for AML Include Risk Stratification to Assist in
Treatment Selection
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. Noteworthy updates include the incorporation of risk stratification based on white blood cell count, the alternative to use cord blood in allogeneic...
Contact: Eileen Scahill
Ohio State University Medical Center
COLUMBUS, Ohio – Older patients with acute myloid leukemia (AML) who were once told that nothing could be done for them are finding new hope – and life – through a clinical trial at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
Preliminary findings of the phase II study suggest that older, previously untreated AML patients can achieve...
